- Home
- CMDB vs CRVS Comparison
CMDB vs CRVS Comparison
Compare CMDB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMDB | CRVS |
|---|---|---|
| Founded | 2023 | 2014 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.8M | 634.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CMDB | CRVS |
|---|---|---|
| Price | $16.16 | $8.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 57.7K | ★ 1.0M |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $799,159,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 152.53 | N/A |
| 52 Week Low | $8.46 | $2.54 |
| 52 Week High | $17.57 | $9.60 |
Technical Indicators
Market Signals| Indicator | CMDB | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.32 |
| Support Level | N/A | $8.31 |
| Resistance Level | N/A | $9.60 |
| Average True Range (ATR) | 0.00 | 0.54 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 0.00 | 26.75 |
Price Performance
Historical ComparisonAbout CMDB Costamare Bulkers Holdings Limited
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).